Buoyed by the strong momentum of its semaglutide franchise in diabetes and obesity, Novo Nordisk’s 2021 net income reached 47.76 billion Danish kroner ($7.59 billion), landing Novo last on Fierce’s top 10 list. Last year’s bottom line wasn’t a huge jump for Novo, which made 42.14 ...